Compounds and methods for inhibiting the interaction of BCL proteins with binding partners

A compound of formula 1:

• or a pharmaceutically acceptable salt thereof;
• wherein independently for each occurrence;
• n is 0, 1, 2, 3, or 4;
• R1 independently for each occurrence is H, alkyl, alkenyl, alkynyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroaralky, halide, hydroxyl, alkoxyl, aryloxy, acyloxy, amino, alkylamino, arylamino, acylamino, aralkylamino, nitro, acylthio, carboxamide, carboxyl, nitrile, —COR5, —CO2R5, —N(R5)CO2R6, —OC(O)N(R5)(R6), —N(R5)SO2R6, or —N(R5)C(O)N(R5)(R6);
• R2 and R3 independently for each occurrence are H, alkyl, alkenyl, alkynyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroaralkyl, or —[C(R5)(R6)]p—R4;
• or has the formula 1a
• wherein
• m is 0, 1, 2, 3, 4, or 5;
• R7 for each occurrence independently is H, alkyl, aryl, alkenyl, halide, hydroxyl, alkoxyl, alkenyloxy, aryloxy, acyloxy, amino, alkylamino, arylamino, acylamino, aralkylamino, nitro, acylthio, carboxamide, carboxyl, nitrile, —OSO3R5, —SO2R5, —S(O)R5, —SR5, —PO2OR5, —OPO2OR5, —COR5, —CO2R5, —OCH2CO2R5, or —OCH2C(O)N(R5)(R6);
• or two occurrences of R7 taken together may form a monocyclic ring between 5-8 ring atoms, of which, one, two, or three atoms are independently S, O, or N;
• R4 is halide, hydroxyl, alkoxyl, aryloxy, acyloxy, amino, alkylamino, arylamino, acylamino, aralkylamino, nitro, acylthio, carboxamide, carboxyl, nitrile, —OSO3R5, —SO2R5, —S(O)R5, —PO2OR5, —OPO2OR5, —COR5, —CO2R5, —N(R5)CO2R6, —OC(O)N(R5)(R6), —N(R5)SO2R6, or —N(R5)C(O)N(R5)(R6);
• and
• each of R5 and R6 independently for each occurrence is H, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, or heteroaralkyl;
• or R5 and R6 taken together form a monocyclic ring with 4-8 ring atoms, of which one, two, or three ring atoms are independently S, O, or N.